Article Information
History
- November 4, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Caroline Engen1,
- Monica Hellesøy2,
- Tara Helén Dowling1,
- Samuli Eldfors3,
- Brent Ferrell4,
- Stein-Erik Gullaksen1,2,
- Mihaela Popa5,
- Atle Brendehaug6,
- Riikka Karjalainen3,
- Eline Mejlænder-Andersen6,
- Muntasir Mamun Majumder3,
- Kimmo Porkka3,
- Randi Hovland6,7,
- Øystein Bruserud2,
- Jonathan Irish4,
- Caroline Heckman3,
- Emmet McCormack1 and
- Bjørn T. Gjertsen1,2,*
- 1Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway
- 2Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway
- 3Institute for Molecular Medicine Finland, FIMM, University of Helsinki, Helsinki, Finland
- 4Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee, United States of America
- 5KinN Therapeutics AS, Bergen, Norway
- 6Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway
- 7Department of Biosciences, University of Bergen, Bergen, Norway
- ↵*Correspondence: Professor Bjørn T. Gjertsen, Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Norway., Tel.: +47 55 97 5000, Fax: +47 55 97 6752, E-mail: bjorn.gjertsen{at}uib.no